HC Wainwright Has Negative Outlook of Omeros FY2029 Earnings

Omeros Corporation (NASDAQ:OMER) – Investment analysts at HC Wainwright dropped their FY2029 earnings per share (EPS) estimates for shares of Omeros in a research report issued to clients and investors on Thursday, August 13th. HC Wainwright analyst B. Folkes now expects that the biopharmaceutical company will earn $3.59 per share for the year, down from their prior estimate of $3.95. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Omeros’ current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Omeros’ FY2030 earnings at $4.62 EPS.

Other analysts also recently issued reports about the stock. D. Boral Capital reaffirmed a “buy” rating and issued a $36.00 target price on shares of Omeros in a research report on Tuesday, April 21st. Wall Street Zen downgraded shares of Omeros from a “buy” rating to a “hold” rating in a research note on Sunday, June 7th. Weiss Ratings raised Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th. Finally, Zacks Research lowered Omeros from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Omeros presently has an average rating of “Moderate Buy” and an average price target of $38.00.

Omeros Trading Up 26.5%

OMER opened at $17.35 on Friday. The company has a market cap of $1.26 billion, a price-to-earnings ratio of 13.55 and a beta of 2.54. The stock has a fifty day simple moving average of $10.74 and a two-hundred day simple moving average of $11.50. Omeros has a 12-month low of $3.94 and a 12-month high of $18.14.

Omeros (NASDAQ:OMER) last released its earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.29. The firm had revenue of $28.53 million during the quarter, compared to analysts’ expectations of $12.69 million.

Insiders Place Their Bets

In other Omeros news, Director Thomas J. Cable sold 7,500 shares of the business’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $11.61, for a total value of $87,075.00. Following the completion of the transaction, the director owned 35,067 shares of the company’s stock, valued at approximately $407,127.87. The trade was a 17.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 10.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in Omeros in the second quarter worth approximately $57,484,000. Vanguard Group Inc. raised its stake in Omeros by 19.9% during the 4th quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company’s stock valued at $68,929,000 after buying an additional 666,357 shares during the last quarter. UBS Group AG lifted its holdings in shares of Omeros by 213.5% during the 4th quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock valued at $38,180,000 after buying an additional 1,513,893 shares during the period. Geode Capital Management LLC boosted its stake in shares of Omeros by 6.3% in the 4th quarter. Geode Capital Management LLC now owns 1,631,350 shares of the biopharmaceutical company’s stock worth $28,026,000 after buying an additional 95,979 shares during the last quarter. Finally, State Street Corp grew its holdings in shares of Omeros by 26.9% in the fourth quarter. State Street Corp now owns 1,573,526 shares of the biopharmaceutical company’s stock worth $27,025,000 after acquiring an additional 333,798 shares during the period. 48.79% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Omeros

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: Omeros reported second-quarter EPS of $0.02, sharply ahead of the $0.27-per-share loss analysts expected and an improvement from a $0.53 loss a year earlier. Revenue of $28.53 million also more than doubled the $12.69 million consensus estimate. Omeros earnings results
• Positive Sentiment: Management’s earnings update emphasized accelerating YARTEMLEA sales, a leaner balance sheet through debt reduction and planned share buybacks. These developments support the case for stronger future cash flow and shareholder returns. Omeros sales momentum and balance sheet update
• Positive Sentiment: HC Wainwright reiterated its Buy rating and maintained a $33 price target, citing strong YARTEMLEA adoption and reduced C5 competition as potential catalysts. Omeros Buy rating and price target
• Neutral Sentiment: Omeros expanded its board from eight to nine members by appointing veteran investor Joseph Schocken. The appointment may strengthen governance and investor engagement, although its direct financial impact is unclear. Omeros appoints Joseph Schocken
• Neutral Sentiment: Trading in Omeros call options rose 235% above typical volume, signaling increased bullish speculation but also potentially greater short-term volatility.
• Negative Sentiment: HC Wainwright reduced its long-term EPS estimates to $3.59 for fiscal 2029 from $3.95 and to $4.62 for fiscal 2030 from $5.00. The analyst remains bullish, but the revisions indicate somewhat lower projected earnings power.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.